Sulindac
SIGMA/S8139 - ≥98.0%
Synonym: (Z)
CAS Number: 38194-50-2
Empirical Formula (Hill Notation): C20H17FO3S
Molecular Weight: 356.41
EC Number: 253-819-2
MDL Number: MFCD00599589
Linear Formula: C20H17FO3S
Product Type: Chemical
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: S8139-25G
This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: S8139-5G
| application(s) | forensics and toxicology veterinary |
| assay | ≥98.0% |
| biological source | synthetic (organic) |
| form | powder |
| InChI | 1S/C20H17FO3S/c1-12-17(9- |
| InChI key | MLKXDPUZXIRXEP-MFOYZWKCSA |
| originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
| Quality Level | 200  |
| SMILES string | CC1=C(CC(O)=O)c2cc(F)ccc2 |
| solubility | methanol: 50 mg/mL |
| technique(s) | gas chromatography (GC): suitable |
| HPLC: suitable |
| Application: | Treatment of human colorectal cancer cell lines induces MRP1 and MRP3 but not other members of the MRP family. Reported to significantly increase the cytotoxicity of the anthracyclines (doxorubicin, daunorubicin and epirubicin), as well as teniposide, VP-16 and vincristine. Sulindac was tested for its effect on heat-induced denaturation of albumin in vitro28 and its ability to bind to human plasma protein.29 |
| Biochem/physiol Actions: | Nonsteroidal anti-inflammatory; preferential inhibitor of COX-1. |
| Biochem/physiol Actions: | Sulindac is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells25,26 and reduces tumor burden in adenomatous polyposis patients.27 |
| Features and Benefits: | This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 g in poly bottle |
| Symbol |   GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H301 - H317 - H334 - H361 |
| Precautionary statements | P201 - P280 - P301 + P310 + P330 - P302 + P352 |
| Hazard Codes | Xn |
| Risk Statements | 63-22-42/43 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98.0% |
| UNSPSC | 12161501 |